Non-interventional Observational Study on WHO-5 Questionnaire Application in Parkinson's Disease

Completed

• Conditions: Parkinson Disease

• Registration Number: NCT00752388
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

To assess the predictive value of sequential administration of WHO-5 and MDI (Major Depression Inventory) for the clinical management of Parkinson Disease (PD) patients by

* determination of the prevalence of depression in PD patients, based on MDI severity categories and the self-rating scale WHO-5, where poor well being was indicated.

* exploration of influencing factors (PD status, therapeutic status) on the prevalence of MDI depression categories.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2008-09-12
• Study First Submitted QC: 2008-09-12
• Study First Posted: 2008-09-15
• Study Start: 2008-11
• Primary Completion: 2008-11
• Status Verified: 2013-11
• Last Update Submitted: 2013-11-18
• Last Update Posted: 2013-11-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1588

Inclusion Criteria

1. PD patients attending one of the participating neurologist practices during 2 fixed weeks in November 2008
2. Idiopathic PD with or without fluctuations
3. Male or female PD patients aged at least 30
4. Ability to reliably complete self-rating scales (WHO-5, MDI) ), according to the physician's judgement.
5. Written informed consent by the patient for study participation.

Read More

Exclusion Criteria

1. PD Patients who only attend the practice to get a prescription and are not seen by the doctor on that day
2. Patients who are not able to understand the questionnaires (e.g. due to mental impairment or language problems).

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of patients with depressive symptoms (based on WHO-5 and MDI) in total and in subgroups	day 1

Secondary Outcome Measures

Name	Time	Method
WHO-5 score and items	day 1
MDI score (for a subgroup of patients with WHO-5 score < 13 or any WHO-5 item rated with 0 or 1)	day 1
Correlation of WHO-5 and MDI (for a subgroup of patients with a WHO-5 score < 13 or any WHO-5 item rated with 0 or 1) in PD patients	day 1
Investigator assessment of the applicability of the WHO-5 for screening for depression in PD patients	day 1

Trial Locations

Locations (15)

Boehringer Ingelheim Investigational Site 2; 🇩🇪 Wuppertal, Germany

Boehringer Ingelheim Investigational Site 13; 🇩🇪 Berlin, Germany

Boehringer Ingelheim Investigational Site 14; 🇩🇪 Berlin, Germany

Boehringer Ingelheim Investigational Site 1; 🇩🇪 Wuppertal, Germany

Boehringer Ingelheim Investigational Site 6; 🇩🇪 Köln, Germany

Boehringer Ingelheim Investigational Site 9; 🇩🇪 Berlin, Germany

Boehringer Ingelheim Investigational Site 8; 🇩🇪 Berlin, Germany

Boehringer Ingelheim Investigational Site; 🇩🇪 Zwickau, Germany

Boehringer Ingelheim Investigational Site 10; 🇩🇪 Berlin, Germany

Boehringer Ingelheim Investigational Site 11; 🇩🇪 Berlin, Germany

Boehringer Ingelheim Investigational Site 12; 🇩🇪 Berlin, Germany

Boehringer Ingelheim Investigational Site 4; 🇩🇪 Mannheim, Germany

Boehringer Ingelheim Investigational Site 5; 🇩🇪 Lüdenscheid, Germany

Boehringer Ingelheim Investigational Site 3; 🇩🇪 Solingen, Germany

Boehringer Ingelheim Investigational Site 7; 🇩🇪 Köln, Germany